Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Cetuximab + Chemotherapy in RAS/BRAF WT mCRC
NCT06776757Phase 2Recruiting
- Sponsor
- Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in metastatic colorectal cancer (mCRC), sponsored by Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences. Started Dec 2023; status: recruiting.
02
Drugs
sintilimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06776757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06776757.